Patent Cases

13,576 decisions across India · European UPC · US PTAB

India 2,847 European UPC 2,007 US PTAB 8,722

Page 89 of 453

patent pending · Jun 30, 2025

Goodfaith Holding Private Limited v.M/S Supreme Wood Products Private Limited

Calcutta High Court · 92085014

The appeal challenges a previous judgment where the defendant's application for revocation of leave granted to the plaintiff under Clause 12 of the Letters Patent was allowed, leading to the dismissal of the suit. The respondent questioned the maintainability of this appeal.
patent LITIGATION · Jun 27, 2025

BAUSSMANN Collated Fasteners GmbH v.Raimund Beck Nageltechnik GmbH

Munich (DE) Central Division - Section · UPC-000597

Procedural order issued by the Court of First Instance of the Unified Patent Court (Central Division, Munich) on June 27, 2025, in a nullity action concerning European Patent EP 4 019 790. The plaintiff seeks revocation of claims 1-4 and 7-13 for lack of novelty and inventive step, while the defendant defends the patent as amended under a main request and eleven auxiliary requests. The court scheduled an interim hearing for July 11, 2025, to address procedural matters including the value of the dispute, settlement possibilities, and the scope of the nullity attacks.
patent LITIGATION · Jun 27, 2025

Centripetal Ltd. v.Palo Alto Networks, Inc. (EP 3 652 914)

Mannheim (DE) Local Division · UPC-000596

Procedural order from the Mannheim Local Division concerning a request by Palo Alto Networks, Inc. (Defendant) to extend the time period for filing its rejoinder in infringement proceedings, reply to the defence to the counterclaim for revocation, and defence against the application to amend European patent EP 3 652 914. The court granted a two-week extension until 14 July 2025, citing the outbreak of hostilities affecting the Defendant's key technical employee based in Israel, but shortened the extension to 9 July 2025 in the event the Defendant files an application for access restrictions under R. 262A RoP.
patent LITIGATION · Jun 27, 2025

Sanofi SA and Others v.Zentiva France and Others

Munich (DE) Local Division · UPC-000595

This is a procedural order from the Local Division Munich of the Unified Patent Court concerning European patent EP 2 493 466. The defendants (Zentiva entities) filed an application under Rule 333 RoP seeking review of a procedural order dated 8 May 2025 regarding case management. The panel confirmed the original order with a minor correction (a typo in the rule citation) and dismissed all of Zentiva's requests.
patent LITIGATION · Jun 27, 2025

Irdeto B.V. v.SZ DJI Technology Co., Ltd., DJI Europe B.V., DJI GmbH, and Solectric GmbH

Mannheim (DE) Local Division · UPC-000594

This order concerns a request by Defendants DJI Europe B.V., DJI GmbH, and Solectric GmbH to extend and harmonize the time periods for filing their Statements of Defence in a patent infringement action brought by Irdeto B.V. concerning EP 2 831 787. The Mannheim Local Division granted a partial extension, extending the deadlines for Defendants 3 and 4 until 14 August 2025 to achieve harmonization, but dismissed the request for a longer extension to 15 September 2025, finding the defendants had not sufficiently demonstrated the need for additional time.
patent terminated or settled · Jun 27, 2025

Apple Inc. v.Vampire Labs, LLC

· IPR2025-01215

Apple and Vampire Labs have reached a settlement that resolves all disputes over U.S. Patent 8,358,103, and they have jointly moved to terminate the pending IPR.
patent · Jun 27, 2025

CentralSquare Technologies, LLC v.Carbyne, Ltd. et al.

· IPR2025-01179

CentralSquare (CST) opposes Carbyne’s request for a good‑cause extension to seek Director Review in IPR2025‑01179, asserting the deadline was missed intentionally and no claim‑construction conflict exists. The email urges the Director to deny the contingent request.
patent terminated or settled · Jun 27, 2025

Apple Inc. v.Vampire Labs, LLC

· IPR2025-01215

Apple and Vampire Labs reached a settlement, prompting a joint motion that led the PTAB to terminate the inter partes review of patent 8,358,103. The Board granted the termination without addressing the merits.
patent · Jun 27, 2025

Apple Inc. v.Vampire Labs, LLC

· IPR2025-01215

Apple and Vampire Labs filed a joint motion asking the PTAB to treat their settlement agreement as business‑confidential and to terminate the IPR.
patent denied · Jun 27, 2025

CentralSquare Technologies, LLC v.Carbyne, Ltd. et al.

· IPR2025-01179

The USPTO denied Carbyne’s request for an extension to file a Director Review, finding no good cause and citing Revvo precedent. CentralSquare’s claim‑construction positions were already known before the deadline.
patent · Jun 27, 2025

Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.

· PGR2025-00052

Merck has filed a post‑grant review petition challenging Halozyme’s U.S. Patent 12,264,345, which claims thousands of modified PH20 hyaluronidase polypeptides. The petition alleges lack of written description, enablement, indefiniteness, and obviousness. The Board must decide whether to institute the proceeding.
patent · Jun 27, 2025

Apple Inc. v.Vampire Labs, LLC

· IPR2025-01215

Apple has filed an IPR petition challenging all 14 claims of Vampire Labs' battery‑charging patent, arguing that the claims are obvious over prior art (Stephens, Horowitz, and Toya) and that discretionary denial is unwarranted. The petition seeks institution of the proceeding and cancellation of the claims.
patent · Jun 27, 2025

Apple Inc. v.CardWare Inc.

· IPR2025-01147

Apple Inc. has filed a petition for inter partes review of CardWare’s U.S. Patent 10,628,820, asserting that all 20 claims are obvious over a range of prior‑art references. The petition highlights lack of patentable weight for printed‑matter limitations and argues a POSITA would have been motivated to combine the teachings.
patent · Jun 27, 2025

Aerin Medical Inc. v.Neurent Medical Ltd. et al.

· IPR2025-01127

Aerin Medical seeks IPR cancellation of Neurent’s ’974 nasal neuromodulation patent, asserting that all 20 claims are obvious over Townley, Wolf‑003/Wolf‑290, and the Angeles console.
patent · Jun 27, 2025

CentralSquare Technologies, LLC v.Carbyne, Ltd. et al.

· IPR2025-01179

CentralSquare Technologies petitions the PTAB to invalidate all 20 claims of Carbyne’s emergency video‑streaming patent, arguing they are anticipated or obvious over two earlier patents. The petition seeks institution of an IPR under §§102 and 103.
patent instituted · Jun 27, 2025

Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.

· PGR2025-00052

Merck Sharp & Dohme LLC successfully petitioned the PTAB to invalidate Halozyme, Inc.'s claims covering a genus of modified PH20 polypeptides. The Board found that the broad scope of the claimed variants lacked adequate written description and enablement support in the original patent disclosure. This decision significantly challenges the breadth of the patented technology in hyaluronidase drug development.
patent instituted · Jun 27, 2025

Apple Inc. v.Vampire Labs, LLC

· IPR2025-01215

The PTAB granted institution for IPR2025-01215, allowing Apple Inc. to challenge Vampire Labs' patent 8358103.
patent instituted · Jun 27, 2025

CentralSquare Technologies, LLC v.Carbyne, Ltd. et al.

· IPR2025-01179

The PTAB granted institution for IPR2025-01179 after reviewing the petitioner's likelihood of prevailing. This decision allows the case to proceed to trial.
patent denied · Jun 27, 2025

Apple Inc. v.CardWare Inc.

· IPR2025-01147

The USPTO Director denied institution for several IPR proceedings involving Apple Inc. and CardWare Inc., meaning no trial will take place.
patent denied · Jun 27, 2025

Aerin Medical Inc. v.Neurent Medical Ltd. et al.

· IPR2025-01127

The USPTO Office Director denied institution of inter partes review (IPR2025-01127) for the challenged patent, meaning no trial will proceed on the claims.
patent LITIGATION · Jun 26, 2025

Visibly Inc. v.Easee B.V., Yves Prevoo, and Easee Holding B.V.

Hamburg (DE) Local Division · UPC-000600

This order from the Hamburg Local Division of the Court of First Instance concerns an application by the Defendants to stay proceedings following the insolvency of two of the three Defendants. Easee B.V. and Easee Holding B.V. were declared bankrupt by the Amsterdam District Court on 27 and 30 May 2025 respectively. The Court granted the stay of proceedings in their entirety for a period of three months under Rule 311.1 RoP, holding that the insolvency of a party does not lead to an automatic stay but that the Court shall stay proceedings upon such declaration.
patent LITIGATION · Jun 26, 2025

Easee B.V., Easee Holding B.V. and managing director v.Visibly Inc.

Luxembourg (LU) · UPC-000599

The Court of Appeal of the Unified Patent Court granted suspensive effect to Easee's appeal against a Hamburg Local Division order requiring Easee to provide EUR 75,000 in security for costs related to a revocation counterclaim in a patent infringement action brought by Visibly Inc. concerning EP 3 918 974. The court found that the first instance order contained a manifest legal error, consistent with its prior ruling in AorticLab vs. Emboline, which established that Article 69(4) UPCA does not provide a legal basis for ordering security for costs at the request of a claimant in an infringement action, nor in response to a counterclaim for revocation. The managing director's application was granted outright, while the Easee companies' application was granted provisionally pending resolution of a competence issue regarding their legal representation following their insolvency.
patent LITIGATION · Jun 26, 2025

Ballinno B.V. v.Kinexon GmbH, Kinexon Sports & Media GmbH, Union des Associations Européennes de Football (UEFA)

Luxembourg (LU) · UPC-000598

Ballinno B.V., proprietor of European Patent EP 1 944 067 concerning a method and system for detecting offside situations, applied for provisional measures against Kinexon companies and UEFA before the Hamburg Local Division. The Local Division ordered Ballinno to provide security for costs of €56,000 and subsequently dismissed the application for provisional measures. On appeal, Ballinno withdrew its requests for provisional measures, rendering the action devoid of purpose, and the Court of Appeal rejected Ballinno's challenge to the security order, ordered Ballinno to bear the costs of the appeal proceedings, and set the value of the dispute for appeal at €100,000.
patent terminated or settled · Jun 26, 2025

Perfect Corporation v.Zugara, Inc.

· IPR2025-01144

Perfect Corp. and Zugara, Inc. settled their IPR dispute over patent 10,482,517. The Board granted a joint motion to terminate the proceeding and kept the settlement agreement confidential.
patent terminated or settled · Jun 26, 2025

Perfect Corporation v.Zugara, Inc.

· IPR2025-01144

Perfect Corp. and Zugara, Inc. entered a confidential settlement and jointly moved to terminate the IPR on Zugara’s virtual‑try‑on patent, citing statutory authority and efficiency concerns.
patent · Jun 26, 2025

Sarepta Therapeutics, Inc. et al. v.Genzyme Corporation et al.

· IPR2025-01194

Sarepta has filed an IPR petition seeking to invalidate claims 3‑6 of Genzyme’s ’542 AAV formulation patent, alleging obviousness over multiple prior‑art references. The petition details how Wu, Konz, Croyle, and Potter collectively disclose all claim limitations.
patent · Jun 26, 2025

Perfect Corporation v.Zugara, Inc.

· IPR2025-01144

Perfect Corp. petitions the PTAB to invalidate 13 claims of Zugara’s virtual‑try‑on patent, asserting obviousness over prior‑art patents and CyberLink’s YouCam 3 publications.
patent · Jun 26, 2025

Sarepta Therapeutics, Inc. et al. v.Genzyme Corporation et al.

· IPR2025-01195

Sarepta has filed an IPR petition challenging Genzyme’s 7,704,721 AAV vector patent, asserting that the claims are obvious over prior‑art purification methods. The petition cites Auricchio, Konz, Potter and related references to support its grounds.
patent denied · Jun 26, 2025

Sarepta Therapeutics, Inc. et al. v.Genzyme Corporation et al.

· IPR2025-01195

The USPTO Director denied institution for several Inter Partes Review petitions, including one concerning Sarepta Therapeutics and Genzyme Corporation's patent 7704721.
patent denied · Jun 26, 2025

Sarepta Therapeutics, Inc. et al. v.Genzyme Corporation et al.

· IPR2025-01194

The USPTO Board denied the institution of IPR proceedings (IPR2025-01194) involving Sarepta Therapeutics and Genzyme Corporation, meaning no trial will proceed on the challenged patent.
1 •••888990•••453
Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →